Search

Displaying results 4791 - 4800 of 10000 in total
  1. Drug

    Tesevatinib

    go.drugbank.com/drugs/DB11973
    Investigational

    In addition, tesevatinib inhibits EphB4, an RTK that is highly expressed in many human tumors and plays a role in promoting angiogenesis. … Tesevatinib is a potent inhibitor of multiple RTKs implicated in driving tumor cell proliferation and tumor vascularization (blood vessel formation).

  2. Drug

    Ditekiren

    go.drugbank.com/drugs/DB19992
    Experimental

    Ditekiren is a small molecule drug. The usage of the INN stem '-kiren' in the name indicates that Ditekiren is a renin inhibitor. Ditekiren has a monoisotopic molecular weight of 929.57 Da.

    Categories: Agents Acting on the Renin-Angiotensin System
  3. Drug

    Phenserine

    go.drugbank.com/drugs/DB04892
    Investigational

    If this is substantiated in an ongoing clinical trial then phenserine may open the door to an entirely new type of treatment for AD. … Axonyx announced on 20 September 2005 that phenserine was ineffective in two curtailed phase 3 trials.

  4. Drug

    Iocarmic acid

    go.drugbank.com/drugs/DB13755
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    PMI-001

    go.drugbank.com/drugs/DB05730
    Experimental

    It is an extract of the roots of an undisclosed perennial shrub which interferes with the production of IL-2 and COX-2 proteins, for the potential treatment of autoimmune diseases, such as rheumatoid arthritis … PMI-001 is a stand-alone, disease-modifying, anti-rheumatic drug (DMARD) being developed by Phytomedics Inc.

  6. Drug

    Aluminum oxide

    go.drugbank.com/drugs/DB11342
    ApprovedWithdrawn

    It is amphoteric in nature, and is used in various chemical, industrial and commercial applications. It is considered an indirect additive used in food contact substances by the FDA.

  7. Drug

    GT 389-255

    go.drugbank.com/drugs/DB05894
    Experimental

    MAD) Phase I trials. … It is expected to block fat absorption with fewer side effects than currently marketed lipase inhibitors.

  8. Drug

    Pracinostat

    go.drugbank.com/drugs/DB05223
    Investigational

    Pracinostat is a novel HDAC inhibitor with improved in vivo properties compared to other HDAC inhibitors currently in clinical trials, allowing oral dosing. … Data demonstrate that Pracinostat is a potent and effective anti-tumor drug with potential as an oral therapy for a variety of human hematological and solid tumors.

  9. Drug

    CTS-21166

    go.drugbank.com/drugs/DB06073
    Investigational

    In 2008, CoMentis revealed this small compound as a transition-state analog inhibitor (structure is currently undisclosed) with excellent properties in brain penetration, selectivity, metabolic stability … CTS-21166 is the only BACE1 inhibitor that has passed Phase I clinical trial thus far.

  10. Drug

    Cloxazolam

    go.drugbank.com/drugs/DB01553
    Experimental

    As well, it has also been studied in Japan in doses of 15-30mg/day as an adjunct in the treatment of intractable epilepsy, for which it has demonstrated effectiveness. … The usual dose of cloxazolam in adults is 3-12mg/day for anti-anxiety.